Surrozen, Inc. is a biotechnology firm dedicated to discovering and advancing pharmaceutical agents that precisely modify the Wnt pathway to facilitate tissue healing and regeneration. The company engineers specialized antibodies intended for use across a broad spectrum of medical conditions impacting organs such as the intestine, liver, eyes (retina, cornea), lungs, kidneys, inner ear (cochlea), skin, pancreas, and central nervous system. Key assets in their development pipeline include SZN-043, a tissue-targeted R-spondin mimetic designed to address severe liver ailments. Another significant candidate is SZN-1326, a distinctive full-length human bi-specific antibody engineered to directly influence Wnt signaling in specific intestinal tissues by engaging with particular Frizzled and LRP receptors found in intestinal crypts. Surrozen, Inc. was established in 2015 and conducts its operations from its base in South San Francisco, California.
